STAAR Surgical Q2 net sales $99.0M (record), EPS $0.15, raises FY2024 guidance

STAAR SURGICAL CO

2024-Q2 EPS reported $0.08 revenue$176,361,000

Record Q2 net sales of $99.0M (up 7% YoY); constant currency $100.4M (+9%).
Net income $7.4M ($0.15 diluted EPS) vs $6.1M ($0.12) YoY; Adjusted EBITDA $22.5M ($0.45).
Gross margin improved to 79.2% from 76.6% YoY, helped by cataract IOL reserve changes.
U.S. ICL sales $5.5M (+25% YoY, +10% sequentially); China ICL sales +3% YoY.
FY2024 net sales guidance raised to $340M-$345M (from $335M-$340M); Adjusted EBITDA ~$42M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.